×

Access Whitepaper

First Name
Last Name
Company
Thank you!
Error - something went wrong!
   

The Challenge of Overreporting: A Fresh Perspective from the FDA

In a recent WCG webinar, Steven Beales, Senior Vice President, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, Robert Temple, the Deputy Director of CDER, and Jacqueline Corrigan-Curay, the Director of the Office of Medical Policy. They discussed overreporting SUSARs and the impact on patient safety. This whitepaper is based largely, but not solely, on that conversation.

About the Author

Steven Beales

An expert in the field of safety reporting technology, Mr. Beales has 25 years of experience in IT, and has spent over 16 years in the pharmaceutical industry. He joined WCG ePharmaSolutions in 2009 and led implementation of the company’s Clinical Trial Portal at Genentech across 100+ countries. In 2015, he led implementation of the Clinical Trial Safety Portal at a top 5 pharma organization, which included a data-driven rules engine configured with safety regulations from those countries, which saved this organization hundreds of millions of dollars. Over 50 million safety alerts have been distributed by these two portals via the cloud. Prior to joining WCG ePharmaSolutions, Mr. Beales was the Chief Software Architect at mdlogix, where he led the implementation of the CTMS systems for Johns Hopkins University, Washington University at St. Louis, the University of Pittsburgh, and the Interactive Autism Network for Autism Speaks.

Follow on Linkedin More Content by Steven Beales
Previous Flipbook
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider

Next Flipbook
Partnering with WCG Saved Small Biotech Over $12K Each Month
Partnering with WCG Saved Small Biotech Over $12K Each Month

New Blog: "Ask the IRB Experts"

Visit Blog